MedeliX
Start asking

Tirzepatide

Mounjaro · ATC code A10BX16

Also known as: Tirzepatid

Key facts
Active substance
Tirzepatide
Drug class
Anti-diabetic medication
ATC code
A10BX16
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Mounjaro 2.5 mg solution for injection in pre-filled pen / Mounjaro 5 mg solution for injection in pre-filled pen / Mounjaro 7.5 mg solution for injection in pre-filled pen
Marketing authorisation holder
Eli Lilly Nederland B.V.
Information as of
2026-10-27

Key facts

Tirzepatide (Mounjaro) is a once-weekly subcutaneous GIP and GLP-1 receptor agonist. It is used for type 2 diabetes and for weight management in obesity or overweight with comorbidity.

What it is used for

  • Insufficiently controlled type 2 diabetes in adults and children aged 10 years and above, with diet and exercise, as monotherapy or add-on
  • Weight management in adults with BMI ≥ 30 kg/m² or ≥ 27 kg/m² with at least one weight-related comorbidity, with reduced-calorie diet and physical activity

Dosing

  • Start 2.5 mg once weekly; after 4 weeks increase to 5 mg; further 2.5 mg increments after at least 4 weeks on each dose
  • Adults: maintenance doses 5 mg, 10 mg or 15 mg; maximum 15 mg once weekly
  • Children 10 years and above (type 2 diabetes): maintenance 5 mg or 10 mg; maximum 10 mg once weekly
  • With a sulphonylurea or insulin: consider reducing their dose (hypoglycaemia risk)
  • Missed dose: give within 4 days, otherwise skip
  • No dose adjustment in renal or hepatic impairment; caution in severe renal impairment

Contraindications

  • Hypersensitivity to the active substance or any of the excipients

Important warnings

  • Acute pancreatitis; discontinue if suspected, do not restart if confirmed
  • Hypoglycaemia with sulphonylureas or insulin
  • Gastrointestinal reactions may cause dehydration and acute renal failure
  • Temporary worsening of diabetic retinopathy possible
  • Consider aspiration risk before general anaesthesia or deep sedation

Side effects

  • Most frequent gastrointestinal: nausea, diarrhoea, vomiting, mostly mild or moderate and mainly during dose escalation
  • Decreased appetite, weight decreased
  • Hypoglycaemia with sulphonylurea or insulin
  • Hypersensitivity reactions; rarely anaphylaxis and angioedema

Interactions

  • Delayed gastric emptying may affect absorption of oral medicines; monitor narrow therapeutic index drugs (e.g. warfarin, digoxin)

Pregnancy and breastfeeding

  • Not recommended in pregnancy; contraception recommended, and discontinue at least 1 month before a planned pregnancy

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • MounjaroEli Lilly Nederland B.V. · EMEA/H/C/005620

Source: European Medicines Agency (EMA), product information

Turkey

  • MounjaroLİLLY İLAÇ TİC. LTD. ŞTİ. · 24 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 3 more European countries
Iceland
Mounjaro
Liechtenstein
Mounjaro
Norway
Mounjaro

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Related calculators

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Mounjaro – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf
  2. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  3. Wikidata (CC0): ATC A10BX.

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.